Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dow University of Health Sciences
With
Higher Education Commission (Pakistan)
Passive immunization using intravenous immunoglobulins (IVIG) has been tested for treating previous viral outbreaks and holds the potential to save lives in the current crisis. Recently researchers from China reported satisfactory recovery of critically ill Corona Virus Disease 2019 (COVID 19) patients when high dose intravenous immunoglobulin (IVIG) were administered.
Research team at Dow University of Health Sciences has purified immunoglobulin (both SARS-CoV 2 antibodies and existing antibodies) from convalescent plasma of COVID19 individuals and pooled to prepared IVIG formulation to treat severe and critically ill COVID-19 patients. To evaluate safety of the formulation animal (rats) safety trials and survival of all the animals were observed.
It is intended to assess safety and efficacy of experimental the IVIG treatment in severe and critically ill COVID 19 patients through phase I/phase II randomized single blinded clinical trial with fifty study participants. FDA outlined criteria for passive immunization using convalescent plasma, which will be used for recruiting participants in the study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Above 18 years of age
Have positive SARS-CoV-2 PCR on nasopharyngeal and/or oropharyngeal swabs
Admitted in isolation ward and ICU of institutes affiliated with DUHS
have severe or critical COVID 19 as judged by the treating physician
Consent given by the patient or first degree relative
You may not be if
Pregnancy
Previous allergic reaction to immunoglobulin treatment
Ig A deficiency
Patient requiring 2 inotropic agents to maintain blood pressures
